Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

@article{Mascarenhas2012BiologyAC,
  title={Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib},
  author={J. Mascarenhas and T. Mughal and S. Verstovsek},
  journal={Current Medicinal Chemistry},
  year={2012},
  volume={19},
  pages={4399 - 4413}
}
Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malignancies. Conventional treatments for the BCR-ABL1-negative MPN including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) have, so far, been unsatisfactory. Following the discovery of dysregulated JAK-STAT signaling in patients with MPN, many efforts have been directed toward the development of molecularly targeted therapies, including inhibitors of JAK1 and JAK2… Expand
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
Kinase signaling and targeted therapy for primary myelofibrosis.
Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 127 REFERENCES
How I treat myelofibrosis.
Molecular aspects of myeloproliferative neoplasms
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
...
1
2
3
4
5
...